Multivariable analysis of risk factors for outcome in the RICOVER-60 study (1222 elderly patients)
| Risk factor . | EFS . | PFS . | OS . | |||
|---|---|---|---|---|---|---|
| HR [95% CI] without rituximab (n = 612) . | HR [95% CI] with rituximab (n = 610) . | HR [95% CI] without rituximab (n = 612) . | HR [95% CI] with rituximab (n = 610) . | HR [95% CI] without rituximab (n = 612) . | HR [95% CI] with rituximab (n = 610) . | |
| Elevated LDH | 1.5 [1.1-1.9] (P = .004) | 1.7 [1.2-2.3] (P = .001) | 1.6 [1.2-2.2] (P = .001) | 2.1 [1.4-2.9] (P < .001) | 1.8 [1.3-2.4] (P = .001) | 1.8 [1.3-2.7] (P < .001) |
| ECOG performance state >1 | 1.8 [1.4-2.5] (P = .001) | 1.6 [1.1-2.3] (P = .001) | 1.7 [1.2-2.3] (P = .001) | 1.6 [1.4-2.9] (P = .016) | 1.8 [1.3-2.5] (P < .001) | 1.9 [1.1-2.5] (P = .009) |
| Stages III and IV | 1.6 [1.2-2.1] (P = .001) | 1.5 [1.1-2.1] (P = .008) | 2.0 [1.5-2.7] (P < .001) | 1.5 [1.0-2.1] (P = .031) | 1.6 [1.2-2.3] (P = .005) | 1.6 [1.1-2.3] (P = .024) |
| >1 Extralymphatic site | 1.4 [1.1-1.9] (P = .017) | 1.0 [0.7-1.4] (P = .958) | 1.7 [1.2-2.2] (P = .001) | 1.1 [0.7-1.6] (P = .672) | 1.7 [1.2-2.4] (P = .002) | 1.1 [0.7-1.6] (P = .817) |
| Age >70 y | 1.2 [1.0-1.6] (P = .1) | 1.6 [1.2-2.1] (P = .002) | 1.4 [1.5-1.7] (P = .02) | 1.6 [1.2-2.2] (P = .003) | 1.6 [1.2-2.2] (P = .001) | 2.0 [1.5-2.9] (P < .001) |
| Male vs female | 1.1 [0.8-1.3] (P = .644) | 1.5 [1.2-2.0] (P = .004) | 1.1 [0.9-1.5] (P = .313) | 1.7 [1.2-2.3] (P = .001) | 1.4 [1.0-1.8] (P = .038) | 1.5 [1.1-2.2] (P = .01) |
| Risk factor . | EFS . | PFS . | OS . | |||
|---|---|---|---|---|---|---|
| HR [95% CI] without rituximab (n = 612) . | HR [95% CI] with rituximab (n = 610) . | HR [95% CI] without rituximab (n = 612) . | HR [95% CI] with rituximab (n = 610) . | HR [95% CI] without rituximab (n = 612) . | HR [95% CI] with rituximab (n = 610) . | |
| Elevated LDH | 1.5 [1.1-1.9] (P = .004) | 1.7 [1.2-2.3] (P = .001) | 1.6 [1.2-2.2] (P = .001) | 2.1 [1.4-2.9] (P < .001) | 1.8 [1.3-2.4] (P = .001) | 1.8 [1.3-2.7] (P < .001) |
| ECOG performance state >1 | 1.8 [1.4-2.5] (P = .001) | 1.6 [1.1-2.3] (P = .001) | 1.7 [1.2-2.3] (P = .001) | 1.6 [1.4-2.9] (P = .016) | 1.8 [1.3-2.5] (P < .001) | 1.9 [1.1-2.5] (P = .009) |
| Stages III and IV | 1.6 [1.2-2.1] (P = .001) | 1.5 [1.1-2.1] (P = .008) | 2.0 [1.5-2.7] (P < .001) | 1.5 [1.0-2.1] (P = .031) | 1.6 [1.2-2.3] (P = .005) | 1.6 [1.1-2.3] (P = .024) |
| >1 Extralymphatic site | 1.4 [1.1-1.9] (P = .017) | 1.0 [0.7-1.4] (P = .958) | 1.7 [1.2-2.2] (P = .001) | 1.1 [0.7-1.6] (P = .672) | 1.7 [1.2-2.4] (P = .002) | 1.1 [0.7-1.6] (P = .817) |
| Age >70 y | 1.2 [1.0-1.6] (P = .1) | 1.6 [1.2-2.1] (P = .002) | 1.4 [1.5-1.7] (P = .02) | 1.6 [1.2-2.2] (P = .003) | 1.6 [1.2-2.2] (P = .001) | 2.0 [1.5-2.9] (P < .001) |
| Male vs female | 1.1 [0.8-1.3] (P = .644) | 1.5 [1.2-2.0] (P = .004) | 1.1 [0.9-1.5] (P = .313) | 1.7 [1.2-2.3] (P = .001) | 1.4 [1.0-1.8] (P = .038) | 1.5 [1.1-2.2] (P = .01) |